Applied Therapeutics, Inc. (NASDAQ:APLT) Stake Trimmed by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. lowered its holdings in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 52.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,961,629 shares of the company's stock after selling 2,150,732 shares during the period. Adage Capital Partners GP L.L.C. owned about 1.69% of Applied Therapeutics worth $1,680,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Private Advisor Group LLC bought a new stake in shares of Applied Therapeutics during the fourth quarter valued at about $35,000. SG Americas Securities LLC raised its position in shares of Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock worth $35,000 after buying an additional 25,601 shares in the last quarter. Intech Investment Management LLC lifted its stake in shares of Applied Therapeutics by 176.1% in the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company's stock worth $45,000 after acquiring an additional 33,567 shares during the period. Dark Forest Capital Management LP boosted its holdings in shares of Applied Therapeutics by 54.5% in the fourth quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company's stock valued at $46,000 after acquiring an additional 18,949 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Applied Therapeutics by 293.9% during the fourth quarter. Legal & General Group Plc now owns 84,018 shares of the company's stock valued at $72,000 after acquiring an additional 62,686 shares during the period. 98.31% of the stock is owned by institutional investors.

Applied Therapeutics Trading Up 11.0 %

NASDAQ:APLT traded up $0.05 during midday trading on Friday, hitting $0.46. 3,882,182 shares of the stock were exchanged, compared to its average volume of 3,198,947. The business has a 50-day moving average price of $0.44 and a two-hundred day moving average price of $2.53. The company has a market capitalization of $65.18 million, a price-to-earnings ratio of -0.29 and a beta of 2.00. Applied Therapeutics, Inc. has a one year low of $0.30 and a one year high of $10.62.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last announced its quarterly earnings data on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.61 million. Sell-side analysts forecast that Applied Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.